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Variant forms of human a-1-proteinase inhibitor (a-l-PI), obtained by the treatment of human Hep G2 cells with specific inhibitors of glycosylation 
were tested for both inhibitory activity and heat stability. All were found to have the same second-order association rate with human neutrophil 
elastase, indicating a lack of importance. of the carbohydrate moiety. In contrast, incompletely glycosylated forms of a-l-PI were found to be heat 
sensitive relative to the mature protein, suggesting a role for carbohydrate in protein stabilization. 
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1. INTRODUCTION 
Proteinase inhibitors represent approximately 10% 
of the proteins in human plasma [l], the major compo- 
nent being a-1-proteinase inhibitor (a-l-PI) [2]. 
Decreased secretion of a variant form of this inhibitor 
(ZZ-phenotype) has been implicated in the development 
of familial emphysema [3], and it has been clearly 
established that this is due to a single base mutation of 
Glu-342 in the normal M-form of the protein to Lys-342 
in the Z-protein [4]. Because of this mutation it has 
been suggested that a normal salt bridge between 
Glu-342 and Lys-290 is interrupted, thus altering the 
conformation of the Z-protein [5]. This, in turn, results 
in aberrant glycosylation and decreased secretion. More 
recently, however, it has been shown that replacing 
Lys-342 with Glu-342 in the M-protein has no effect on 
secretion [6]. Thus, the absence of a salt bridge is not 
directly responsible for the failure to adequately secrete 
the Z-protein. 
In our laboratory we have been investigating the pro- 
perties of intermediate glycosylation forms of cu-l-PI 
(M-variant) synthesized by human Hep G2 cells. These 
proteins were isolated from cells grown in the presence 
of specific inhibitors of the post-translational glycosyla- 
tion process. This approach has been taken by others to 
compare secretion rates of plasma proteins with dif- 
ferent carbohydrate side chain attachments in a rat 
hepatocyte system (10-131. While we were interested in 
confirming their results using human hepatocytes, our 
primary goal was to determine whether carbohydrate 
side-chain structure had any effect on the inhibitory 
function of f~-I-PI. 
2. MATERIALS AND METHODS 
Swainsonine, I-deoxynojirimycin and I-deoxymannojirimycin 
While some of the Z-protein is found in plasma (ap- 
proximately 10% of normal levels), the majority re- 
mains in the liver packaged in inclusion bodies [7]. Ex- 
amination of the carbohydrate structure of both forms 
of this protein indicates that the secreted Z-protein is 
identical to that of the normal M-form, while that re- 
tained in the liver is primarily composed of high man- 
nose side chains [8,9]. Such data would indicate that 
some of the Z-variant is post-translationally modified 
in a correct manner and that the major problem is due 
to an interruption in the normal rate of trimming of the 
high mannose forms of this protein. 
were from Calbiochem. Tunicamycin and MeG-Suc-L-Ala-L-Ala-L- 
Pro-L-Val-pNA were from Sigma. Antisera (goat) to cy-l-PI, 
cr-1-antichymotrypsin (U-l-Achy), and cY-t-macroglobulin ((u-2-M) 
were products of Atlantic Antibodies. MEM-cell culture medium was 
from Gibco. Human neutrophil elastase was prepared as previously 
described [14]. 
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Cell culture and inhibitorpurification: Human Hep G2 cells (kindly 
provided by Dr B.B. Knowles, Wistar Institute, Philadelphia, PA) 
were grown in Dulbecco’s MEM plus 10% fetal calf serum (Flow 
Laboratories) with fresh medium added every 3 days. Nearly con- 
fluent human Hep G2 cells were washed twice with serum-free 
medium and exposed to a number of glycosylation inhibitors, in- 
cluding tunicamycin (3.5 pg/ml), swainsonine (3.5 pg/ml), l-deoxy- 
nojirimycin (0.5 mM), and I-deoxymannojirimycin (0.5 mM), all of 
which were dissolved in 0.1% bovine serum albumin. Cells were in- 
cubated with these inhibitors for 4 days with replacement of the 
medium every 24 h. Collected media were dialyzed vs 0.005 M sodium 
phosphate buffer, pH 6.8, and lyophilized. (u-l-PI was then purified 
from this powder according to the procedure of Pannell et al. [15] 
with the addition of a final purification step on a Mono Q FPLC 
system. Human plasma cu-l-PI (M- and Z-forms) was purified in an 
identical manner. The rate of secretion of cu-l-PI and other plasma 
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proteins by treated Hep G2 cells was followed by rocket immunoelec- 
trophoresis [ 161. 
The Z-form of (Y-I-PI was obtained from livers of ZZ homozygotes 
by homogenization of liver tissue in 0.05 M Tris-HCI, pH 7.5,0.25 M 
sucrose. The microsomal fraction obtained by differential centrifuga- 
tion was resuspended in 0.05 M glycine-NaOH buffer, pH 10.0, 
sonicated for one min, and shaken overnight. After lowering the pH 
to 7.0, the sample was centrifuged at 105 OOOxg for 1 h, the superna- 
tant dialyzed vs 0.05 M Tris-HCl, pH 8.0, and chromatographed on 
DEAE-cellulose, followed by Mono-Q FPLC. 
Assays for inhibitory activity were performed against neutrophil 
elastase. Samples were incubated with excess enzyme for 1 min in 0.03 
M sodium phosphate buffer, 0.15 M NaCl, pH 7.4. Residual elastase 
amidase activity was then measured using MeO-Suc-L-Ala-L-Ala-L- 
Pro-L-Val-pNA, as previously described [17]. Second order associa- 
tion rate constants for the interaction of individual inhibitors with 
elastase were performed in a similar manner, using equal activities of 
enzyme and inhibitor, incubating for various time periods, and 
measuring residual enzyme activity. 
Heat inactivation of (r-l-PI preparations was obtained by in- 
cubating in 0.03 M sodium phosphate, pH 6.8 at 60°C for varying 
time periods, removing aliquots, and measuring residual inhibitory 
activity. 
3. RESULTS AND DISCUSSION 
Hep G2 cells are known to synthesize at least twenty 
serum proteins [ 181, including several proteinase in- 
hibitors [19]. Using control cells we were easily able to 
demonstrate the production of a-l-PI, a-l-Achy, and 
CY-2-M by rocket immunoelectrophoresis (Table I). 
In the presence of tunicamycin the secretion of 
a-l-PI was diminished by over 45%, a result in line with 
the data obtained by Gross et al. [13] while using a rat 
hepatocyte system. 1-deoxynojirimycin was less effec- 
tive, while both swainsonine and l-deoxymannojiri- 
mycin did not influence the secretion of (Y-I-PI. These 
results suggest hat the lack of carbohydrate on a-l-PI 
in tunicamycin-treated cells reduces its secretion 
dramatically, while the presence of glucose residues on 
uncompleted side chains (1-deoxynojirimycin treat- 
ment) also retards secretion. In contrast, the presence 
of high mannose side chains (swainsonine and deoxy- 
mannojirimycin treatments) does not apparently affect 
secretion of (~-l-P1 from Hep G2 cells, as previously 
shown [13] in the rat system. Similar data were found 
for both a-l-Achy and a-2-M, although the latter ap- 
peared to be less effected by treatment of cells with 
1-deoxynojirimycin. 
Studies on the inhibition of both human neutrophil 
elastase and porcine pancreatic trypsin by the various 
purified, partially glycosylated forms of a-l-PI in- 
dicated that each had essentially the same k,,, for the in- 
dividual enzymes (Table II). 
This indicates that in the human system, at least, car- 
bohydrate is not at all important for inhibitory activity. 
As reported previously [20], we also found that the Z- 
plasma form of a-l-PI had a k,,, value with elastase 
which was about 40% lower than that of the normal M- 
form. Significantly, we found the same result with the 
Z-liver protein. Since each carries different car- 
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Table I 
Effect of inhibitors of glycosylation on serpin secretion in human Hep 
G2 cells 
Treatment Inhibitor synthesis (vo) 
&l-PI U-l-Achy a-2-M 
Control 100 100 100 
+ Tunicamycin 51 nd 58 
+ Swainsonine 116 106 109 
+ I-Deoxynojirimycin 68 89 72 
+ I-Deoxymannojirimycin 103 95 83 
Media from cultured Hep G2 cells (lo6 cells) were harvested after 24 
h incubation in the presence or absence of inhibitors and tested for in- 
dividual proteins by quantitative rocket immunoelectrophoresis. nd, 
not determined. 
Table II 
Second-order association rate constants for the inhibition of 
neutrophil elastase by human (r-l-PI glycosylation variants 
Inhibitor variant kars (M-l. s-l) 
MM-Plasma 2.4 x 10’ 
ZZ-Plasma 1.1 x 10’ 
ZZ-Liver 1.1 x 10’ 
Hep G2 cells 
Control 2.7 x 10’ 
+ Swainsonine 2.8 x 10’ 
+ Tunicamycin 2.6 x 10’ 
+ I-Deoxynojirimycin 2.2 x 10’ 
+ I-Deoxymannojirimycin 2.3 x 10’ 
bohydrate side chains due to the incomplete glycosyla- 
tion of the Z-liver protein [8,9], it is clear that the 
reason for the lower kass is due to differences in protein 
conformation provided by the amino acid mutation at 
residue 342 and not due to aberrations in carbohydrate 
Heat Inactivation of Q-PI Glycosylation Variants 
Hep G2 Culture Cell Medium 
D control 
. Tunicomp,” Tr*ofad 
. ?.*omronma Tr*Obd 
50 60 70 
TIME (min) 
Fig. 1. Effect of heat on the stability of cu-l-PI glycosylatiOn variants. 
Samples were heated at 60°C and residual activity against human 
neutrophil elastase measured. 
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structure. Comparable results were obtained when por- 
cine pancreatic trypsin was tested with the kass being 
two orders of magnitude lower, as previously reported 
WI. 
Although carbohydrate does not appear to have any 
influence on the inhibitory activity of (r-l-PI, it is im- 
portant in the maintenance of stability. As shown in 
Fig. 1 both the M-form of a-l-PI isolated from plasma 
and that obtained from control Hep G2 cell media 
showed similar labilities in heat inactivation studies. In 
contrast, all of the partially glycosylated inhibitors 
isolated from treated cells had markedly reduced 
stability. Included in this latter list was the plasma Z- 
form of ~-l-P1 despite the fact that it is known to con- 
tain completed complex carbohydrate side chains [S]. 
Presumably, this is also due to the altered protein con- 
formation of this mutant form of inhibitor [4]. 
REFERENCES 
111 
121 
[31 
141 
Travis, J. and Salvesen, G. (1983) Annu. Rev. Biochem. 52, 
655-709. 
Travis, J. and Johnson, D. (1981) Methods Enzymol. 80, 
754-765. 
Eriksson, S. (1%5) Acta Med. Stand. 177 (Suppl.) 432, 20-24. 
Jeppsson, J-O. (1976) FEBS Lett. 65, 195-197. 
151 
161 
[71 
181 
191 
1101 
illI 
iI21 
H31 
1141 
1151 
[I61 
[I71 
WI 
t191 
ml 
WI 
Loebermann, H., Tokuoka, R., Deisenhofer, J. and Huber, R. 
(1984) J. Mol. Biol. 177, 531-556. 
McCracken, A., Kruse, K. and Brown, J. (1989) Mol. Cell. Biol. 
9, 1406-1414. 
Sharp, H.L., Bridges, R.A., Krivit, W. and Freier, E.F. (1969) 
J. Lab. Clin. Med. 73, 934-939. 
Chan, SK., Rees, DC., Li S-C. and Li, Y-T. (1976) J. Biol. 
Chem. 251, 471-476. 
Hertz, A. and Harpaz, N. (1980) Can. J. Biochem. 58,644-648. 
Gross, V., Geiger, T., Tran-Thi, T-A., Gauthier, F. and 
Heinrich, P.C. (1982) J. Biochem. 129, 317-323. 
Gross, V., Andus, T., Tran-Thi, T-A., Schwarz, R.T., Decker, 
K. and Heinrich, P.C. (1983) J. Biol. Chem. 258, 12203-12209. 
Gross, V., Tran-Thi, T-A., Vosbeck, K. and Heinrich, P.C. 
(1983) J. Biol. Chem. 258, 4032-4036. 
Gross, V., Staube, K., Tran-Thi, T-A., McDowell, W., 
Schwarz, T., Decker, K., Gerok, W. and Heinrich, P.C. (1985) 
J. Biochem. 150,41-46. 
Baugh, R. and Travis, J. (1976) Biochemistry 15, 836-841. 
Pannell, R., Johnson, D. and Travis, J. (1974) Biochemistry 13, 
5439-5445. 
Weeke, B. (1973) Stand. J. Immunol. (SuppLl), 37-46. 
McRae, B., Nakajima, K., Travis, J. and Powers, J.C. (1980) 
Biochemistry 19, 3973-3979. 
Knowles, B.B., Howe, C.D. and Aden, D.P. (1980) Science 209, 
497-499. 
Lodish, H.F., Kong, N., Snider, M. and Strous, G. J.A.M. 
(1983) Nature 304, 80-83. 
Ogushi, F., Fells, G.A., Hubbard, R.C., Straus, S.D. and 
Crystal, R.G. (1987) J. Clin. Invest. 80, 1366-1374. 
Beatty, K., Bieth, J. and Travis, J. (1980) J. Biol. Chem. 255, 
3931-3936. 
127 
